Thiazole Compounds Inhibiting RSV Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for human respiratory syncytial virus (RSV) infection lack effective and safe therapies, particularly for at-risk populations such as infants, the elderly, and immunocompromised individuals, with existing options like ribavirin having significant side effects and limited efficacy.
Innovation Solution
Development of specific compounds and pharmaceutical compositions that inhibit RSV infection and replication, including compounds of formula (A) and their pharmaceutically acceptable salts, which can be used to treat or prevent RSV infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ribavirin is used to treat RSV infection, then antiviral activity is achieved, but significant side effects occur including anemia, fatigue, and birth defects
Solution Approach 1:
The patent extracts and eliminates the harmful side effects of existing antiviral therapy (ribavirin) while retaining the desired antiviral efficacy. The new compounds are designed to specifically inhibit RSV replication without causing the anemia, fatigue, and teratogenic effects associated with ribavirin, thus separating the therapeutic benefit from the harmful consequences.
Solution Approach 2:
The patent changes the chemical parameters and molecular structure of antiviral agents by developing novel thiazole compounds with different pharmacological profiles. These structural modifications result in compounds that maintain antiviral activity against RSV but exhibit improved safety profiles with reduced or eliminated side effects compared to ribavirin.
2Adaptability or versatility
If no effective antiviral therapy is available, then treatment options are limited, but vaccine development has failed due to low tolerance to side effects in at-risk populations
Solution Approach 1:
The patent develops antiviral compounds that can be administered as short-duration treatments to achieve effective RSV clearance, avoiding the need for prolonged exposure that would increase cumulative side effects. This approach allows treatment of at-risk populations with reduced tolerance for side effects, expanding adaptability of treatment options.
Solution Approach 2:
The patent modifies the pharmacological parameters of antiviral therapy by creating compounds with improved safety margins that can be tolerated by vulnerable populations including infants, the elderly, and immunocompromised patients, thereby expanding the versatility of available treatment options.
3Reliability
If palivizumab is used for prophylaxis, then hospitalization frequency is reduced in high-risk populations, but it is only approved for prophylactic use and not for treatment
Solution Approach 1:
The patent creates antiviral compounds with multi-functional utility that can serve both prophylactic and therapeutic indications. The novel thiazole compounds are effective both in preventing RSV infection and in treating established infections, making them universally applicable across different clinical scenarios and expanding adaptability beyond the limited prophylactic use of palivizumab.
Solution Approach 2:
The patent develops compounds that can dynamically adapt to different clinical needs, functioning effectively whether administered before infection (prophylaxis) or after infection establishment (treatment). This dynamic versatility allows the same compound to serve multiple indications, unlike palivizumab which is restricted to prophylactic use only.
Data Source
AI summary
This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.